2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1736

A Randomized, Controlled, Multicenter, 2‑Arm, Parallel‑Group, Double-Blind Study To Demonstrate The Equivalence Of CT-P10 To Innovator Rituximab With Respect To Pharmacokinetic Profile In Patients With Rheumatoid Arthritis
Abstract Number: 1797

A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis
Abstract Number: 2668

A Randomized, Double-Blind, Dose Ranging Study Comparing FX006, An Intra-Articular (IA) Sustained-Release Formulation Of Triamcinolone Acetonide (TCA), To An Approved Injectable Suspension Of TCA In Patients With Osteoarthritis (OA) Of The Knee
Abstract Number: 493

A Real-World Risk Analysis Of Biological Treatment (Adalimumab and Etanercep) In Country With High Prevalence Of Tuberculosis and Hepatitis B/C
Abstract Number: 582

A Real-World Survey Of Clinical Practice Among Rheumatologists and Nephrologists In The United States Reveals Differences In Care Of Non-Nephritis Systemic Lupus Erythematosus and Lupus Nephritis As Compared With American College Of Rheumatology Treatment Guidelines
Abstract Number: 2812

A Rheumatology Objective Structured Clinical Examination Using Challenging Patient Scenarios Shows Trainee Use Of Medical Jargon Correlates Inversely With Patient Perceptions Of Professionalism
Abstract Number: 2100

A Scoping Review On Leisure Activity Expectations After Total Hip Or Knee Arthroplasty Due To Arthritis
Abstract Number: 891

A Single Amino Acid In The β1 Chain Of HLA-DR Explains The Majority Of The HLA Association With Giant Cell Arteriti
Abstract Number: 800

A Strategy For Selecting Individuals With RA For Reduction Of Anti-TNF Therapy Using Combined Clinical and Ultrasound Assessment
Abstract Number: 1385

A Study Of Natural Killer Cell Subfractions In Abatacept Therapy For Rheumatoid Arthritis
Abstract Number: 1923

A Study To Determine Patient Satisfaction With a Nurse-Led Injection Clinic In Rheumatology
Abstract Number: 150

A Subset Of Osteoarthritis Individuals Has Elevated IL-6 Pathway Activation Associated With Worse Symptoms
Abstract Number: 589

A Survey Of Physician and Patient Satisfaction With Control Of Systemic Lupus Erythematosus and Lupus Nephritis
Abstract Number: 498

A Systematic Review and Meta-Analysis Comparing Low- Versus High-Dose Rituximab For Rheumatoid Arthritis
Abstract Number: 2519

A Systemic Lupus Erythematosus (SLE) Diagnostic Test Based On DNA Methylation Signatures From Peripheral Blood Mononuclear Cells

« Previous Page
1
…
4
5
6
7
8
…
193
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].